+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Hunter Syndrome Treatment Market - Global Forecast 2026-2032- Product Image
Hunter Syndrome Treatment Market - Global Forecast 2026-2032- Product Image
New

Hunter Syndrome Treatment Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 183 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5532898
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Hunter Syndrome Treatment Market is experiencing an important evolution, shaped by scientific innovation and the convergence of new diagnostic, therapeutic, and care delivery practices. Senior executives and stakeholders must navigate a shifting landscape defined by emerging modalities, regulatory change, and renewed focus on patient pathways to support sustainable growth and access.

Market Snapshot: Hunter Syndrome Treatment Market

The Hunter Syndrome Treatment Market grew from USD 1.27 billion in 2025 to USD 1.38 billion in 2026. It is projected to expand at a CAGR of 9.04%, reaching USD 2.33 billion by 2032. These figures highlight strong commercial momentum, reflecting the impact of innovation in molecular therapies and expanded care delivery models. As demand rises, the market environment reflects diverse stakeholders’ needs, from providers and payers to technology partners and policymakers worldwide.

Scope & Segmentation: Comprehensive Perspective

  • Therapeutic Modalities: The spectrum includes Enzyme Replacement Therapy with agents such as Idursulfase and Idursulfase Beta, Gene Therapy using Adeno Associated Virus Vector and Lentiviral Vector, Hematopoietic Stem Cell Transplant (both Allogeneic and Autologous), and Supportive Therapy (covering Nutritional Support, Pain Management, Physical Therapy, and Respiratory Support). Each modality brings unique clinical and commercial considerations.
  • Routes of Administration: Intravenous, oral, and subcutaneous options are central to enhancing clinical workflow, patient adherence, and experience. The administration method can drive operational requirements and shape service strategies.
  • Age Cohorts: Market dynamics differ across Adult (including Middle Aged, Senior, and Young Adult) and Pediatric (Adolescent, Child, Infant, Toddler) groups, as each cohort presents specific dosing, response, and caregiver involvement needs.
  • Care Settings: Delivery spans Ambulatory Surgical Centers, Home Infusion, Hospital, and Specialty Clinic environments, each necessitating tailored infrastructure and reimbursement models to ensure seamless care and appropriate funding streams.
  • Geographic Regions: Distinctive patterns are seen across the Americas, Europe, Middle East & Africa, and Asia-Pacific, revealing differentiated regulatory policies, access frameworks, and service modalities that shape both market strategy and operational deployment.

Key Takeaways: Strategic Themes in Hunter Syndrome Treatment

  • Innovative molecular therapies and improved enzyme formulations are supporting the expansion of available treatment options. However, ongoing variation in long-term efficacy highlights the necessity for robust patient stratification and better outcome monitoring to maximize therapeutic value.
  • Regional payer systems and differences in regulatory approach remain powerful determinants of market access, influencing how companies achieve early adoption and maintain competitive positioning. Adaptable entry and partnership models are critical for sustainable success.
  • Earlier intervention, underpinned by the extension of newborn and early childhood screening, is shifting the market focus towards disease-modifying therapies and coordinated care frameworks, with regional variations in policy and infrastructure adoption.
  • Payers are moving toward innovative agreements, such as outcomes-based reimbursement and alternative contracting methods, to balance the need for fiscal responsibility with the imperative to meet patient needs in dynamic reimbursement environments.
  • Integrated delivery models, including home infusion and telehealth-linked care, play a key role in improving therapy adherence and reducing operational burdens, addressing the unique challenges of scaling patient-centric services globally.
  • Collaboration between pharmaceutical developers, clinicians, and patient advocacy groups is central to aligning evidence generation with evolving regulatory, access, and patient outcome priorities in this changing landscape.

Tariff Impact: Navigating Supply Chain and Access Challenges

With the introduction of new tariff policies in the United States from 2025, stakeholders participating in the Hunter Syndrome Treatment Market face heightened complexity in biologics and gene therapies supply chains. Manufacturers and distributors are recalibrating sourcing strategies and increasing nearshoring to minimize customs-related risks. Healthcare providers and hospital buyers are responding by renegotiating procurement arrangements, bolstering inventory practices, and prioritizing collaborative manufacturing efforts to avert potential access disruptions. For clinical trial sponsors, these trade-induced changes pose an urgent need to redesign international logistics, further emphasizing the importance of transparency and adaptability in supply chain management to guarantee ongoing patient care.

Methodology & Data Sources: Ensuring Robust Hunter Syndrome Market Insights

This report leverages a blended methodology, combining secondary research from regulatory, clinical trial, and published literature sources with primary interviews among clinical, supply chain, and payer stakeholders. Cross-validation, scenario mapping, and sensitivity reviews were undertaken to safeguard data accuracy and recommendations amid evolving therapy durability and regulatory landscapes.

Why This Report Matters: Actionable Insights for Strategic Decision-Makers

  • Provides deep segmentation across modalities, age cohorts, and geographies, empowering tailored strategies for pipeline development, market launch, and partnership initiatives.
  • Delivers ongoing tracking of regulatory and reimbursement evolution, enabling executives to build evidence, access, and commercialization tactics attuned to payer and clinical realities.
  • Equips market participants with pragmatic responses to tariff, operational, and supply chain risks, ensuring operational resilience and consistent patient access even in volatile environments.

Conclusion

The Hunter Syndrome Treatment Market stands at a pivotal point, driven by advances in treatment science, evolving operational models, and region-specific strategy requirements. Decision-makers who emphasize resilience, innovation, and coordinated care will be best positioned to achieve sustainable growth in this complex environment.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Hunter Syndrome Treatment Market, by Treatment Type
8.1. Enzyme Replacement Therapy
8.1.1. Idursulfase
8.1.2. Idursulfase Beta
8.2. Gene Therapy
8.2.1. Adeno Associated Virus Vector
8.2.2. Lentiviral Vector
8.3. Hematopoietic Stem Cell Transplant
8.3.1. Allogeneic Transplant
8.3.2. Autologous Transplant
8.4. Supportive Therapy
8.4.1. Nutritional Support
8.4.2. Pain Management
8.4.3. Physical Therapy
8.4.4. Respiratory Support
9. Hunter Syndrome Treatment Market, by Route Of Administration
9.1. Intravenous
9.2. Oral
9.3. Subcutaneous
10. Hunter Syndrome Treatment Market, by Patient Age Group
10.1. Adult
10.1.1. Middle Aged
10.1.2. Senior
10.1.3. Young Adult
10.2. Pediatric
10.2.1. Adolescent
10.2.2. Child
10.2.3. Infant
10.2.4. Toddler
11. Hunter Syndrome Treatment Market, by End User
11.1. Ambulatory Surgical Center
11.2. Home Infusion
11.3. Hospital
11.4. Specialty Clinic
12. Hunter Syndrome Treatment Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Hunter Syndrome Treatment Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Hunter Syndrome Treatment Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Hunter Syndrome Treatment Market
16. China Hunter Syndrome Treatment Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. Abbott
17.6. ArmaGen, Inc.
17.7. Bayer AG
17.8. BioMarin Pharmaceutical Inc.
17.9. Denali Therapeutics
17.10. F. Hoffmann-La Roche Ltd
17.11. Green Cross Corporation
17.12. GSK Plc.
17.13. Inventiva S.A.
17.14. JCR Pharmaceuticals Co., Ltd.
17.15. Johnson & Johnson Services, Inc.
17.16. Medtronic
17.17. Regenxbio Inc.
17.18. Sangamo Therapeutics, Inc.
17.19. Stryker Corporation
17.20. Takeda Pharmaceutical Company Limited
17.21. Zimmer Biomet
List of Figures
FIGURE 1. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL HUNTER SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL HUNTER SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA HUNTER SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY IDURSULFASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY IDURSULFASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY IDURSULFASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY IDURSULFASE BETA, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY IDURSULFASE BETA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY IDURSULFASE BETA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADENO ASSOCIATED VIRUS VECTOR, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADENO ASSOCIATED VIRUS VECTOR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADENO ASSOCIATED VIRUS VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY LENTIVIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY LENTIVIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY LENTIVIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ALLOGENEIC TRANSPLANT, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ALLOGENEIC TRANSPLANT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ALLOGENEIC TRANSPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY AUTOLOGOUS TRANSPLANT, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY AUTOLOGOUS TRANSPLANT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY AUTOLOGOUS TRANSPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPORT, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY RESPIRATORY SUPPORT, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY RESPIRATORY SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY RESPIRATORY SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY MIDDLE AGED, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY MIDDLE AGED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY MIDDLE AGED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SENIOR, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SENIOR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SENIOR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY YOUNG ADULT, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY YOUNG ADULT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY YOUNG ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY CHILD, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY CHILD, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY CHILD, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY INFANT, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY INFANT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY INFANT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY TODDLER, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY TODDLER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY TODDLER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY HOME INFUSION, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY HOME INFUSION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY HOME INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 103. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 104. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 105. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
TABLE 106. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 107. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 108. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 109. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 110. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 111. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2032 (USD MILLION)
TABLE 112. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 113. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 114. NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 116. NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
TABLE 117. NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 118. NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 119. NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 120. NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 121. NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 122. NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2032 (USD MILLION)
TABLE 123. NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 124. NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 125. LATIN AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 126. LATIN AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 127. LATIN AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
TABLE 128. LATIN AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 129. LATIN AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 130. LATIN AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 131. LATIN AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 132. LATIN AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 133. LATIN AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2032 (USD MILLION)
TABLE 134. LATIN AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 135. LATIN AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2032 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 147. EUROPE HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 148. EUROPE HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 149. EUROPE HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
TABLE 150. EUROPE HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 151. EUROPE HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 152. EUROPE HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 153. EUROPE HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 154. EUROPE HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 155. EUROPE HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2032 (USD MILLION)
TABLE 156. EUROPE HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 157. EUROPE HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 158. MIDDLE EAST HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 159. MIDDLE EAST HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 160. MIDDLE EAST HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
TABLE 161. MIDDLE EAST HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 162. MIDDLE EAST HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 163. MIDDLE EAST HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 164. MIDDLE EAST HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 165. MIDDLE EAST HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 166. MIDDLE EAST HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2032 (USD MILLION)
TABLE 167. MIDDLE EAST HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 168. MIDDLE EAST HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 169. AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 170. AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 171. AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
TABLE 172. AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 173. AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 174. AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 175. AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 176. AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 177. AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2032 (USD MILLION)
TABLE 178. AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 179. AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 180. ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 181. ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 182. ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
TABLE 183. ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 184. ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 185. ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 186. ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 187. ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 188. ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2032 (USD MILLION)
TABLE 189. ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 190. ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 191. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 192. ASEAN HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 193. ASEAN HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 194. ASEAN HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
TABLE 195. ASEAN HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 196. ASEAN HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 197. ASEAN HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 198. ASEAN HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 199. ASEAN HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 200. ASEAN HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2032 (USD MILLION)
TABLE 201. ASEAN HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 202. ASEAN HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 203. GCC HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 204. GCC HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 205. GCC HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
TABLE 206. GCC HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 207. GCC HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 208. GCC HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 209. GCC HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 210. GCC HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 211. GCC HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2032 (USD MILLION)
TABLE 212. GCC HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 213. GCC HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 214. EUROPEAN UNION HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 215. EUROPEAN UNION HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 216. EUROPEAN UNION HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
TABLE 217. EUROPEAN UNION HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 218. EUROPEAN UNION HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 219. EUROPEAN UNION HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 220. EUROPEAN UNION HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 221. EUROPEAN UNION HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 222. EUROPEAN UNION HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2032 (USD MILLION)
TABLE 223. EUROPEAN UNION HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 224. EUROPEAN UNION HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 225. BRICS HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 226. BRICS HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 227. BRICS HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
TABLE 228. BRICS HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 229. BRICS HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 230. BRICS HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 231. BRICS HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 232. BRICS HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 233. BRICS HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2032 (USD MILLION)
TABLE 234. BRICS HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 235. BRICS HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 236. G7 HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 237. G7 HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 238. G7 HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
TABLE 239. G7 HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 240. G7 HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 241. G7 HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 242. G7 HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 243. G7 HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 244. G7 HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2032 (USD MILLION)
TABLE 245. G7 HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 246. G7 HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 247. NATO HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 248. NATO HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 249. NATO HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
TABLE 250. NATO HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 251. NATO HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 252. NATO HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 253. NATO HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 254. NATO HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 255. NATO HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2032 (USD MILLION)
TABLE 256. NATO HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 257. NATO HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 258. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 259. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 260. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 261. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
TABLE 262. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 263. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 264. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 265. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 266. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 267. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2032 (USD MILLION)
TABLE 268. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 269. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 270. CHINA HUNTER SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 271. CHINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 272. CHINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
TABLE 273. CHINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 274. CHINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 275. CHINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 276. CHINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 277. CHINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 278. CHINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2032 (USD MILLION)
TABLE 279. CHINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 280. CHINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Hunter Syndrome Treatment market report include:
  • Abbott
  • ArmaGen, Inc.
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • Denali Therapeutics
  • F. Hoffmann-La Roche Ltd
  • Green Cross Corporation
  • GSK Plc.
  • Inventiva S.A.
  • JCR Pharmaceuticals Co., Ltd.
  • Johnson & Johnson Services, Inc.
  • Medtronic
  • Regenxbio Inc.
  • Sangamo Therapeutics, Inc.
  • Stryker Corporation
  • Takeda Pharmaceutical Company Limited
  • Zimmer Biomet

Table Information

Report AttributeDetails
No. of Pages183
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 1.38 Billion
Forecasted Market Value ( USD ) by 2032 $ 2.33 Billion
Compound Annual Growth Rate9.0%
Regions CoveredGlobal
No. of Companies Mentioned18

Related Topics

Related Reports

Hunter Syndrome Pipeline Analysis Report 2025 - Product Image

Hunter Syndrome Pipeline Analysis Report 2025

  • Report
  • 200 Pages
  • Global
From
Hunter Syndrome Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Hunter Syndrome Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Hunter Syndrome - Pipeline Insight, 2025 - Product Image

Hunter Syndrome - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Lysosomal Storage Diseases Market - Global Forecast 2025-2032 - Product Image

Lysosomal Storage Diseases Market - Global Forecast 2025-2032

  • Report
  • 185 Pages
  • Global
From
Hunter Syndrome Treatment - Global Strategic Business Report - Product Image

Hunter Syndrome Treatment - Global Strategic Business Report

  • Report
  • 280 Pages
  • Global
From

About the Market

Mucopolysaccharidosis (MPS) is a group of rare, inherited metabolic disorders caused by the deficiency of lysosomal enzymes. These enzymes are responsible for breaking down complex sugars called glycosaminoglycans (GAGs). Without these enzymes, GAGs accumulate in the body, leading to a wide range of symptoms, including skeletal deformities, organ enlargement, and cognitive impairment. Treatment for MPS is focused on managing symptoms and preventing further progression of the disease. Immune disorders drugs are used to treat MPS, including enzyme replacement therapy (ERT), substrate reduction therapy (SRT), and gene therapy. ERT involves the administration of a recombinant enzyme to replace the missing enzyme, while SRT works by reducing the production of GAGs. Gene therapy is a newer approach that involves the introduction of a healthy gene into the patient's cells to replace the defective gene. Companies in the MPS drug market include Sanofi, Shire, Pfizer, and Ultragenyx Pharmaceuticals. Sanofi is a French pharmaceutical company that produces Aldurazyme, an ERT drug for MPS I. Shire is a biopharmaceutical company that produces Elaprase, an ERT drug for MPS II. Pfizer is an American pharmaceutical company that produces Vimizim, an ERT drug for MPS IV. Ultragenyx Pharmaceuticals is a biopharmaceutical company that produces Mep Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.